Data from a Phase II trial show rifaximin may significantly improve quality-of-life symptoms in patients with irritable bowel syndrome with diarrhea. Researchers, presenting at the ACG annual meeting, found that the rifaximin group showed greater improvements over the placebo group in overall quality-of-life scores as well as subscale scores for body image, relationships, dysphoria and health concerns.

Related Summaries